Aim: To evaluate intraocular biodistribution of fluorescent nanoparticles composed of dexamethasone bound to chitosan after intravitreal administration in rabbit eyes.
Material And Methods: The chitosan and gelatin based nanoparticles were synthetized using a reverse emulsion-double crosslinking technique (ionic and covalent) and then dexamethasone was bound. Two units of 1% suspension of these nanoparticles in saline solution were injected intravitreally into rabbit eyes. The histologic sections obtained at 72 hours were analyzed by confocal microscopy.
Results: The chitosan-fluorescein conjugate bound to dexamethasone was present in all ocular tissues at 72 hours. The nanoparticles were present in the retina and lens in a larger amount than in the other ocular tissues.
Conclusions: The reverse emulsion-double crosslinking technique was efficient in synthesizing a biocompatible polymeric nanosystem. The in vivo study of intraocular biodistribution of fluorescein-marked nanoparticles capable of binding dexamethasone revealed their affinity for the retina and lens after intravitreal administration.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Enhancing non-viral DNA delivery systems: Recent advances in improving efficiency and target specificity.
J Control Release
December 2024
Clinical and Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia. Electronic address:
DNA-based therapies are often limited by challenges such as stability, long-term integration, low transfection efficiency, and insufficient targeted DNA delivery. This review focuses on recent progress in the design of non-viral delivery systems for enhancing targeted DNA delivery and modulation of therapeutic efficiency. Cellular uptake and intracellular trafficking mechanisms play a crucial role in optimizing gene delivery efficiency.
View Article and Find Full Text PDFUltrasensitive detection of uveal melanoma using [F]AlF-NOTA-PRGD2 PET imaging.
EJNMMI Res
July 2024
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Jiangsu Province, China.
Background: Uveal melanoma (UM) is the most common primary intraocular tumor in adults, and early detection is critical to improve the clinical outcome of this disease. In this study, the diagnostic effectiveness of [F]AlF-NOTA-PRGD2 (an investigational medicinal product) positron emission tomography (PET) imaging in UM xenografts and UM patients were evaluated. The cell uptake, cell binding ability and in vitro stability of [F]AlF-NOTA-PRGD2 were evaluated in 92-1 UM cell line.
View Article and Find Full Text PDFIn vitro and in vivo studies of ocular topically administered NLC for the treatment of uveal melanoma.
Int J Pharm
July 2024
Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Via Valdisavoia 5, 95123 Catania, Italy; NANOMED, Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania. Electronic address:
Uveal melanoma is one of the most common and aggressive intraocular malignancies, and, due to its great capability of metastasize, it constitutes the most incident intraocular tumor in adults. However, to date there is no effective treatment since achieving the inner ocular tissues still constitutes one of the greatest challenges in actual medicine, because of the complex structure and barriers. Uncoated and PEGylated nanostructured lipid carriers were developed to achieve physico-chemical properties (mean particle size, homogeneity, zeta potential, pH and osmolality) compatible for the ophthalmic administration of (S)-(-)-MRJF22, a new custom-synthetized prodrug for the potential treatment of uveal melanoma.
View Article and Find Full Text PDFOcular permeability, intraocular biodistribution of lipid nanocapsule formulation intended for retinal drug delivery.
Eur J Pharm Biopharm
June 2023
Institute for Ophthalmic Research, University of Tübingen, Elfriede-Aulhorn Straße 5-7, 72076 Tübingen, Germany. Electronic address:
Recently, cGMP analogues have been investigated for the treatment of inherited retinal degenerations (IRD) using intravitreal injections. However, higher vitreous elimination rates limit the possibility to treat the retina with small molecule drugs. Here, we investigated the potential of lipid nanocapsules (LNCs) as vehicles to reduce clearance and prolong the delivery of cGMP analogue, CN03 to the retinal photoreceptors.
View Article and Find Full Text PDFFramework Nucleic Acids as Blood-Retinal-Barrier-Penetrable Nanocarrier for Periocular Administration.
ACS Appl Mater Interfaces
January 2023
Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine and Department of Ophthalmology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
Designing an ocular drugs delivery system that can permeate the outer blood-retinal barrier (oBRB) is crucial for the microinvasive or noninvasive treatment of ocular fundus diseases. However, due to the lack of a nanocarrier that can maintain structure and composition at the oBRB, only intravitreal injection at the eyeball can deliver therapeutics directly to the ocular fundus via paracellular and intercellular routes, despite the intraocular operations risks. Here, we demonstrated tetrahedral framework nucleic acids (tFNAs) can penetrate the oBRB and deliver therapeutic nucleic acids to the retina of the rat eye in vivo following subconjunctival injection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!